Heteroresistance to Colistin in Multidrug-Resistant Acinetobacter baumannii
Top Cited Papers
- 1 September 2006
- journal article
- Published by American Society for Microbiology in Antimicrobial Agents and Chemotherapy
- Vol. 50 (9) , 2946-2950
- https://doi.org/10.1128/aac.00103-06
Abstract
Multidrug-resistant Acinetobacter baumannii has emerged as a significant clinical problem worldwide and colistin is being used increasingly as “salvage” therapy. MICs of colistin against A. baumannii indicate its significant activity. However, resistance to colistin in A. baumannii has been reported recently. Clonotypes of 16 clinical A. baumannii isolates and ATCC 19606 were determined by pulsed-field gel electrophoresis (PFGE), and colistin MICs were measured. The time-kill kinetics of colistin against A. baumannii ATCC 19606 and clinical isolate 6 were investigated, and population analysis profiles (PAPs) were conducted. Resistance development was investigated by serial passaging with or without exposure to colistin. Five different PFGE banding patterns were found in the clinical isolates. MICs of colistin against all isolates were within 0.25 to 2 μg/ml. Colistin showed early concentration-dependent killing, but bacterial regrowth was observed at 24 h. PAPs revealed that heteroresistance to colistin occurred in 15 of the 16 clinical isolates. Subpopulations (8 to 10 9 CFU/ml) of ATCC 19606, and most clinical isolates grew in the presence of colistin 3 to 10 μg/ml. Four successive passages of ATCC 19606 in broth containing colistin (up to 200 μg/ml) substantially increased the proportion of the resistant subpopulations able to grow in the presence of colistin at 10 μg/ml from 0.000023 to 100%; even after 16 passages in colistin-free broth, the proportion only decreased to 2.1%. This represents the first demonstration of heterogeneous colistin-resistant A. baumannii in “colistin-susceptible” clinical isolates. Our findings give a strong warning that colistin-resistant A. baumannii may be observed more frequently due to potential suboptimal dosage regimens recommended in the product information of some products of colistin methanesulfonate.Keywords
This publication has 42 references indexed in Scilit:
- Colistin Methanesulfonate Is an Inactive Prodrug of Colistin against Pseudomonas aeruginosaAntimicrobial Agents and Chemotherapy, 2006
- Colistin: The Revival of Polymyxins for the Management of Multidrug-Resistant Gram-Negative Bacterial InfectionsClinical Infectious Diseases, 2005
- Colistin treatment in patients with ICU-acquired infections caused by multiresistant Gram-negative bacteria: the renaissance of an old antibioticClinical Microbiology & Infection, 2005
- Cure of multidrug-resistant Acinetobacter baumannii bacteraemia with continuous intravenous infusion of colistinScandinavian Journal of Infectious Diseases, 2005
- Evaluation of colistin as an agent against multi-resistant Gram-negative bacteriaPublished by Elsevier ,2004
- Serological and molecular evidence of Rickettsia helvetica in DenmarkScandinavian Journal of Infectious Diseases, 2004
- Susceptibility of the Acinetobacter calcoaceticus–A. baumannii complex to imipenem, meropenem, sulbactam and colistinInternational Journal of Antimicrobial Agents, 2004
- Stability of Colistin and Colistin Methanesulfonate in Aqueous Media and Plasma as Determined by High-Performance Liquid ChromatographyAntimicrobial Agents and Chemotherapy, 2003
- Carbapenem resistance mediated by Beta-lactamases in clinical isolates ofAcinetobacter baumannii in SpainEuropean Journal of Clinical Microbiology & Infectious Diseases, 1998
- Selection of Aminoglycoside-Resistant Variants of Pseudomonas aeruginosa in an in Vivo ModelThe Journal of Infectious Diseases, 1982